Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONNECTURE INC
Report date April 25, 2018 · Filed April 27, 2018
Section 16 reporting ended · disclosed 2018-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy David A. Jones, Jr. Revocable Trust | 0 |
Reported balance
After 2018-04-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-04-25 · Other · Disposed 57,696 · Balance 0 F1: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Chrysalis Ventures II L.P. | 0 |
Reported balance
After 2018-04-25 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-04-25 · Other · Disposed 4,007,162 · Balance 0 F1: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Chrysalis Ventures II L.P. | 0 |
Reported balance
After 2018-04-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-25 · Other · Disposed 2,000 · Balance 0 F3: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date. F1: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Chrysalis Ventures II L.P. | 0 |
Reported balance
After 2018-04-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-04-25 · Other · Disposed 1,000 · Balance 0 F4: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date. F1: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares.
F2: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein.
F3: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date.
F4: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date.
HUMANA INC
Report date April 20, 2023 · Filed April 20, 2023
Section 16 reporting ended · disclosed 2023-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Humana CommonSEC Table I · non-derivative | Direct | 380 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 380 F5: Includes 380 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/23. Total shares received will be pro-rated based on number of months served on the Board prior to separation. |
| Humana CommonSEC Table I · non-derivative | IndirectSee Footnote | 800 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 800 F1: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. |
| Humana CommonSEC Table I · non-derivative | IndirectSee Footnote | 32,440 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 32,440 F4: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,892 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 5,892 F2: Annual Director's fee payable in stock units which have been deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 95 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 95 F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee.
F2: Annual Director's fee payable in stock units which have been deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).
F3: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F4: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock.
F5: Includes 380 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/23. Total shares received will be pro-rated based on number of months served on the Board prior to separation.
Tristar Acquisition I Corp.
Report date July 18, 2023 · Filed August 02, 2023
Section 16 reporting ended · disclosed 2023-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 5,750 |
Reported balance
After 2023-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-18 · Other · Disposed 19,250 · Balance 5,750 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date. F2: These shares were sold pursuant to (i) a securities purchase agreement, dated as of July 18, 2023, by and between the Issuer, Tristar Holdings I LLC ("Prior Sponsor") and Navy Sail International Limited and (ii) founder share transfer agreements, each dated as of July 18, 2023, by and between Chunyi (Charlie) Hao and each holder of Class B ordinary shares other than Prior Sponsor. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date.
F2: These shares were sold pursuant to (i) a securities purchase agreement, dated as of July 18, 2023, by and between the Issuer, Tristar Holdings I LLC ("Prior Sponsor") and Navy Sail International Limited and (ii) founder share transfer agreements, each dated as of July 18, 2023, by and between Chunyi (Charlie) Hao and each holder of Class B ordinary shares other than Prior Sponsor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2023 Filed Aug 2, 2023 06:04 UTC | Tristar Acquisition I Corp. TRIS · Entity 109724 | OtherClass B Ordinary Shares · Derivative | 19,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-017714 · doc4.xml · derivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Class A Ordinary Shares · 19,250 shares Expires not disclosed F1 · derivative.exercise_price: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date. F2 · kind: These shares were sold pursuant to (i) a securities purchase agreement, dated as of July 18, 2023, by and between the Issuer, Tristar Holdings I LLC ("Prior Sponsor") and Navy Sail International Limited and (ii) founder share transfer agreements, each dated as of July 18, 2023, by and between Chunyi (Charlie) Hao and each holder of Class B ordinary shares other than Prior Sponsor. F1 · derivative.exercise_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date. F1 · derivative.expiration_date: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date. F1 · balance_after: As described in the Issuer's registration statement on Form S-1 (File No. 333-255009), the Class B ordinary shares will automatically convert into Class A ordinary shares (a) automatically at the time of the registrant's initial business combination and (b) at any time and from time to time at the option of the holders thereof. Such conversion will be on a one-for-one basis, subject to adjustment as described therein, and the Class B ordinary shares have no expiration date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 14:37 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-005464 · form4.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 32,440 F6 · shares: Shares disposed of represent a gift/charitable donation, effective February 28, 2023, in which no value was received in return. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 17:37 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 380 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000124 · form4.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380 F5 · balance_after: Includes 380 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/23. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 15:18 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 15,000 | $501.72 | $7,525,800.00 |
DisclosureSEC source: 0001062993-22-024440 · form4.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,028 F7 · shares: Shares contributed by the David Jones Jr Revocable Trust to an exchange fund in return for shares of the exchange fund. The Humana Inc. common stock was valued at $501.72 per share, using close of business prices on the day prior to the exchange date, for purposes of determining the number of shares of the exchange fund issued to the Revocable Trust. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| April 28, 2022 Filed Dec 23, 2022 15:18 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 11,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-024440 · form4.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 57,028 F6 · shares: Shares disposed of represent gift/charitable donation effective April 28, 2022, in which no value was received in return. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 18:03 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 412 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000549 · form4.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412 F5 · balance_after: Includes 412 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/22. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 20:06 UTC | Tristar Acquisition I Corp. TRIS · Entity 109724 | PurchaseClass B ordinary shares · Derivative | 25,000 | $11.50 Strike: $0.00 | $287,500.00 |
DisclosureSEC source: 0001062993-21-011276 · form4.xml · derivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A ordinary shares · 25,000 shares Expires not disclosed F1 · kind: These shares of Class B ordinary shares are subject to potential forfeiture and transfer restrictions by and between the Reporting Person and Tristar Holdings I LLC ("Sponsor") pursuant to a Founder Share Purchase Agreement dated November 17, 2021. F2 · derivative.exercise_date: These Class B ordinary shares will automatically convert into Class A ordinary shares on a one-for-one basis for no additional consideration concurrently with or immediately following the consummation of the initial business combination by the Issuer, on a one-for-one basis, subject to the adjustments described in the Issuer's prospectus on Form S-1 filed on October 14, 2021 (the "Prospectus"). The Class B ordinary shares have no expiration date. F2 · derivative.expiration_date: These Class B ordinary shares will automatically convert into Class A ordinary shares on a one-for-one basis for no additional consideration concurrently with or immediately following the consummation of the initial business combination by the Issuer, on a one-for-one basis, subject to the adjustments described in the Issuer's prospectus on Form S-1 filed on October 14, 2021 (the "Prospectus"). The Class B ordinary shares have no expiration date. F2 · derivative.underlying: These Class B ordinary shares will automatically convert into Class A ordinary shares on a one-for-one basis for no additional consideration concurrently with or immediately following the consummation of the initial business combination by the Issuer, on a one-for-one basis, subject to the adjustments described in the Issuer's prospectus on Form S-1 filed on October 14, 2021 (the "Prospectus"). The Class B ordinary shares have no expiration date. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 13:07 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 4,800 | $401.00 | $1,924,800.00 |
DisclosureSEC source: 0000049071-21-000125 · edgar.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 67,925 F6 · shares: Shares contributed by the David Jones Jr. Revocable Trust to an exchange fund in return for shares of the exchange fund. The Humana Inc. common stock was valued at $401.00 per share, using close of business price on the day prior to the exchange date, for purposes of determining the number of shares of the exchange fund issued to the Revocable Trust. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Includes 453 shares that vested on 12/31/20 and transferred to trust on 1/4/21. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 14:48 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-21-000010 · edgar.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403 F5 · balance_after: Includes 403 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/21. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 14:47 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 5,000 | $392.76 | $1,963,800.00 |
DisclosureSEC source: 0000049071-20-000171 · edgar.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 77,272 F6 · shares: Shares contributed by the David Jones Jr Revocable Trust to an exchange fund in return for shares of the exchange fund. The Humana Inc. common stock was valued at $392.76 per share, using close of business prices on the day prior to the exchange date, for purposes of determining the number of shares of the exchange fund issued to the Revocable Trust. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| June 30, 2020 Filed Dec 21, 2020 14:47 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-20-000171 · edgar.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 72,272 F7 · shares: Shares reported represent a gift/chartiable donation, effective June 30, 2020, in which no value was received in return. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:25 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 5,800 | $256.19 | $1,485,902.00 |
DisclosureSEC source: 0000049071-20-000065 · edgar.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 82,272 F6 · shares: Shares contributed by the David Jones Jr Revocable Trust to an exchange fund in return for shares of the exchange fund. The Humana Inc. common stock was valued at $256.19 per share, using close of business prices on the day prior to the exchange date, for purposes of determining the number of shares of the exchange fund issued to the Revocable Trust. F4 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:51 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-20-000004 · edgar.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F5 · balance_after: Includes 453 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/20. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 F5 · balance_after: Includes 588 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2019. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:18 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000083 · edgar.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 86,826 F7 · price: This transaction represents a gift/charitable donation effective June 14, 2018. This is not a market transaction and no value was received in return for the shares. F5 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 17:09 UTC | CONNECTURE INC CNXR · Entity 167208 | OtherSeries B Convertible Preferred Stock · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010891 · doc4.xml · derivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Chrysalis Ventures II L.P. Disclosed balance after: 0 Underlying: Common Stock · 618,170 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date. F1 · kind: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · price: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F4 · price: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.expiration_date: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.underlying_shares: The Series B Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $1.91 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series B Convertible Preferred Stock was equal to approximately 618.17 shares. The Series B Preferred Stock was convertible at any time and had no expiration date. F1 · balance_after: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2 · ownership.nature: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 17:09 UTC | CONNECTURE INC CNXR · Entity 167208 | OtherSeries A Convertible Preferred Stock · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010891 · doc4.xml · derivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Chrysalis Ventures II L.P. Disclosed balance after: 0 Underlying: Common Stock · 585,160 shares Expires not disclosed F3 · derivative.exercise_price: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date. F1 · kind: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · price: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F3 · price: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.underlying_shares: The Series A Convertible Preferred Stock was convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially was $4.50 per share, subject to customary anti-dilution adjustments. As of April 25, 2018, the number of shares of Common Stock deliverable upon conversion of each share of Series A Convertible Preferred Stock was equal to approximately 292.58 shares. The Series A Preferred Stock was convertible at any time and had no expiration date. F1 · balance_after: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2 · ownership.nature: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 17:09 UTC | CONNECTURE INC CNXR · Entity 167208 | OtherCommon Stock | 4,007,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010891 · doc4.xml · nonDerivative · entry 2 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Chrysalis Ventures II L.P. Disclosed balance after: 0 F1 · kind: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · price: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · balance_after: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F2 · ownership.nature: These shares were held directly by CV II. Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 17:09 UTC | CONNECTURE INC CNXR · Entity 167208 | OtherCommon Stock | 57,696 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-010891 · doc4.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David A. Jones, Jr. Revocable Trust Disclosed balance after: 0 F1 · kind: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · price: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. F1 · balance_after: On April 25, 2018, FP Healthcare Merger Sub Corporation ("Merger Sub") and FP Healthcare Holdings, Inc. ("Parent") completed its merger (the "Merger") with and into the Issuer, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2018, by and among Parent, Merger Sub and the Issuer. In connection with the completion of the Merger, each of Mr. Jones and Chrysalis Partners II L.P. ("CV II") contributed all of the shares of Common Stock and Preferred Stock, as applicable, held by him or it, as applicable, (the "Rollover Shares") to the Parent. At the effective time of the Merger, each of the Rollover Shares were canceled and ceased to exist and no consideration was paid in respect of such Rollover Shares. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000011 · edgar.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434 F6 · balance_after: Includes 658 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2018. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 18:19 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000157 · edgar.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 96,050 F6 · price: This transaction represents a gift/charitable donation effective August 23, 2017. This is not a market transaction and no value was received in return for the shares. F7 · balance_after: On March 22, 2017 Mr. Jones transferred 27,050 indirect shares from his grantor retained annuity trust (GRAT #2) to his revocable trust account. On June 2, 2017 he transferred 52,198 indirect shares from his grantor retained annuity trust (GRAT #1) to his revocable trust account. These transactions were not reportable pursuant to SEC rule 16a-13. GRAT #1 and GRAT #2 have a balance of 0 shares, and therefore were removed from Table I reporting. On August 23, 2017 he gifted 4,000 shares from his revocable trust account. This reflects the balance following these three transactions. F5 · ownership.nature: Shares held by a revocable trust account (Dec 2009), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock. Read SEC document |
| May 18, 2017 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 200 | $230.04 | $46,008.02 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 6 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 800 F1 · ownership.nature: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. Amounts reported reflect equal sales and subsequent holdings from each trust on the reported dates that were inadvertently omitted from prior filings. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 19:10 UTC | CONNECTURE INC CNXR · Entity 167208 | PurchaseSeries B Convertible Preferred Stock · Derivative | 1,000 | $1,000.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-17-020635 · doc4.xml · derivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Chrysalis Ventures II, L.P. Disclosed balance after: 1,000 Underlying: Common Stock · 523,560 shares Expires not disclosed F1 · derivative.exercise_price: The Series B Convertible Preferred Stock is convertible into Common Stock at a rate equal to (i) the sum of (a) the original purchase price ($1,000 per share) plus (b) all accrued and unpaid dividends thereon up to but not including the conversion date, divided by (ii) the conversion price of the Common Stock at such time, which initially is $1.91 per share, subject to customary adjustments. F2 · derivative.expiration_date: The Series B Convertible Preferred Stock has no expiration date. F3 · ownership.nature: Shares held directly by Chrysalis Ventures II, L.P. ("CV II"). Mr. Jones is a Managing Member of Chrysalis Partners II, LLC, the general partner of CV II. Mr. Jones disclaims beneficial ownership of the shares held by CV II, except to the extent of any pecuniary interest therein. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 16:58 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 27,000 | $205.04 | $5,536,169.10 |
DisclosureSEC source: 0000049071-17-000040 · edgar.xml · nonDerivative · entry 6 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,050 F9 · price: Shares sold at prices ranging from $204.51 to $206.43. F7 · ownership.nature: Shares held by grantor retained annuity trust (GRAT #2) exempt from Rule 16(a)-13, on which reporting person is the sole trustee. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:21 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 761 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000003 · edgar.xml · nonDerivative · entry 1 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 F8 · balance_after: Includes 761 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2017. Read SEC document |
| October 21, 2016 Filed Oct 24, 2016 17:47 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 54,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-16-000180 · edgar.xml · nonDerivative · entry 5 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,050 F6 · ownership.nature: On September 17th, 2015, the reporting person transferred 106,248 shares of Humana Inc. common stock from his revocable trust to a new grantor retained annuity trust (GRAT) exempt from Rule 16(a)-13, on which he is the sole trustee. On October 21, 2016 reporting person transferred 54,050 shares from the GRAT to his revocable trust. Read SEC document |
| October 21, 2016 Filed Oct 24, 2016 17:47 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 54,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-16-000180 · edgar.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 52,198 F6 · ownership.nature: On September 17th, 2015, the reporting person transferred 106,248 shares of Humana Inc. common stock from his revocable trust to a new grantor retained annuity trust (GRAT) exempt from Rule 16(a)-13, on which he is the sole trustee. On October 21, 2016 reporting person transferred 54,050 shares from the GRAT to his revocable trust. Read SEC document |
| August 11, 2014 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 200 | $120.24 | $24,048.02 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 5 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000 F1 · ownership.nature: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. Amounts reported reflect equal sales and subsequent holdings from each trust on the reported dates that were inadvertently omitted from prior filings. Read SEC document |
| June 10, 2014 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 400 | $124.49 | $49,797.96 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 4 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,200 F1 · ownership.nature: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. Amounts reported reflect equal sales and subsequent holdings from each trust on the reported dates that were inadvertently omitted from prior filings. Read SEC document |
| March 16, 2012 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 400 | $86.32 | $34,528.24 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 3 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,600 F1 · ownership.nature: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. Amounts reported reflect equal sales and subsequent holdings from each trust on the reported dates that were inadvertently omitted from prior filings. Read SEC document |
| November 16, 2011 Filed Jan 4, 2019 21:10 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 600 | $88.05 | $52,830.24 |
DisclosureSEC source: 0000049071-19-000011 · edgar.xml · nonDerivative · entry 2 JONES DAVID A JR/KY · CIK 0001025393 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,000 F1 · ownership.nature: Shares held in two trusts for the benefit of reporting person's son/daughter, respectively, in each case where the reporting person is the sole trustee. Amounts reported reflect equal sales and subsequent holdings from each trust on the reported dates that were inadvertently omitted from prior filings. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.